JAK2 and diffuse large B-cell lymphoma: In addition, the novel macrocyclic pyrimidine-based selective oral inhibitor of JAK2/JAK2(V617F) and FLT3 kinases, pacritinib (SB1518), which blocks phosphorylation of STAT1, STAT3 and STAT5 has also been suggested for further investigations in clinical studies of patients with relapsed/refractory DLBCL [317, 319, 320] (Additional file 1: Table S6).